Alemtuzumab effective in poor-genetic-risk chronic lymphocytic leukaemia

Subcutaneous alemtuzumab (MabCampath) is as effective in the genetically hard-to-treat patients with refractory chronic lymphocytic leukaemia (CLL) as in all patients with refractory CLL... click link for more info.

Continue to Alemtuzumab effective in poor-genetic-risk chronic lymphocytic leukaemia on Medical News Today.

Medical Buzz delivers the most recent headlines from the medical world. Diseases, cures, accidents, medicin. Click below for more headlines ...
Medical buzz